Beactica Announces Fragment-Based Drug Discovery Agreement
"We are pleased to work with Janssen and look forward to utilising Beactica's platform to support the progress of one of their prioritized programmes" said Beactica CEO, Dr. Per Källblad. "Fragment-based approaches to drug discovery are creating new pathways towards small-molecule leads of high-quality and Beactica has worked hard to win a reputation for being at the cutting-edge of advances".
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.